Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897286 | 0.94 | TSHR (0.39) | TSHR | |
| SCHEMBL106035 | 0.88 | — | — | |
| SCHEMBL3034212 | 0.81 | TSHR (0.33) | TSHR | |
| SCHEMBL3026558 | 0.76 | TSHR (0.37) | TSHR | |
| SCHEMBL2542461 | 0.74 | LMNA (0.34) | — | |
| SCHEMBL1486046 | 0.74 | — | — | |
| SCHEMBL106757 | 0.73 | ITGB2 (0.41) | — | |
| SCHEMBL9466531 | 0.72 | — | — | |
| SCHEMBL21462 | 0.68 | ITGB2 (0.50) | — | |
| SCHEMBL5750764 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755956-B1 | 2,4-DISUBSTITUTED 5-FLUORO-PYRIMIDINES AS SELECTIVE CDK9 INHIBTORS | BAYER IP GMBH (DE) | 2016-05-18 | — | — | EP | claimed |
| US-9108926-B2 | Disubstituted 5-fluoro-pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-18 | — | — | US | claimed |
| US-20140228387-A1 | DISUBSTITUTED 5-FLUORO-PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-14 | — | — | US | claimed |
| JP-4554364-B2 | — | — | 2010-09-29 | — | — | JP | claimed |
| US-6977262-B2 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-12-20 | — | — | US | claimed |
| EP-1539739-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-15 | — | — | EP | claimed |
| EP-1537106-A1 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2005-06-08 | — | — | EP | claimed |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-03-18 | — | — | US | claimed |
| WO-2004020435-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-11 | — | — | WO | claimed |
| WO-2004014910-A1 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-02-19 | — | — | WO | claimed |
| EP-1355909-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-10-29 | — | — | EP | claimed |
| WO-2002062795-A9 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2002-10-10 | — | — | WO | claimed |
| WO-2002062795-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | WO | claimed |
| US-9708293-B2 | N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-18 | — | — | US | disclosed |
| US-9670161-B2 | 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-06 | — | — | US | disclosed |
| EP-2909200-B1 | N-(PYRIDIN-2-YL)PYRIMIDIN-4-AMINE DERIVATIVES CONTAINING A SULFONE GROUP | Bayer Pharma AG (DE) | 2016-11-23 | — | — | EP | disclosed |
| EP-1355909-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002062795-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | WO | disclosed |
| EP-0839133-A1 | 4,9-ETHANO-BENZO(F)ISOINDOLE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS | Aventis Pharma S.A. (FR) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997003050-A1 | 4,9-ETHANO-BENZO(F)ISOINDOLE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS | RHONE-POULENC RORER S.A. (FR) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | GSK3B, GSK3A, PYGB | TSHR 4767/4885CLK1 1292/4885DYRK1A 245/4885 |
| US-20140228387-A1 | DISUBSTITUTED 5-FLUORO-PYRIMIDINES | DPYD, DHFR, TYMP | TSHR 2961/4885CLK1 3195/4885DYRK1A 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.